

LLS Research Grants in Force: 2016

Last Name	First Name	Institution	Project Title	Program
Alt	Frederick	Immune Disease Institute (fka) The CBR Institute for Biomedical Research, Inc.	Pathogenetic Mechanisms and Therapeutic Targets in B-Cell Lymphoma	SCOR
Licht	Jonathan	Northwestern University	Chromatin Mechanisms And Epigenetic Targeting In Hematological Malignancies	SCOR
Adams	Jerry	Walter & Eliza Hall Institute of Medical Research	Apoptosis in Leukemogenesis and Therapy	SCOR
Cierpicki	Tomasz	Regents of the University of Michigan	Targeting MMSET in multiple myeloma	TRP Basic
Gao	Xiaofei	Whitehead Institute for Biomedical Research	Dissecting HIF-1a-mediated mechanisms of hematopoietic progenitor self-renewal	Fellow
Chang	Xiu-bao	Mayo Clinic Arizona	Immunomodulatory drugs` target cereblon and its downstream substrates	TRP Basic
Ghobrial	Irene	Dana-Farber Cancer Institute	Deciphering and Targeting Clonal evolution in Hematologic Malignancies	SCOR
Heslop	Helen	Baylor College of Medicine	Immunotherapy for Hematologic Malignancies	SCOR
Mitsiades	Constantine	Dana-Farber Cancer Institute	Individualizing myeloma treatment with BET bromodomain inhibitors	TRP Basic
Nguyen	Thang	California Institute of Technology	Identification of specific substrates for the Cereblon E3 ubiquitin ligase	Fellow
Yi	Qing	Cleveland Clinic Foundation	Targeting macrophages to improve chemosensitivity in high risk melanoma	TRP Basic
Jones	Richard	The Johns Hopkins University School of Medicine	Chemoprotection by the Bone Marrow Niche Mediated by Cytochrome P450 Enzymes	TRP Basic
Gilbert	Luke	The Regents of the University of California, San Francisco	A combined chemical and genetic approach to explore the therapeutic window.	Fellow
Plate	Lars	The Scripps Research Institute	Selective Remodeling of the ER Proteostasis Network to Reduce Amyloid Light Chain Secretion for Myeloma Treatment	Fellow
Matsui	William	The Johns Hopkins University School of Medicine	GDF15-SOX2 signaling and self-renewal in multiple myeloma	TRP Basic
Munshi	Nikhil	Dana-Farber Cancer Institute	Prognostic and therapeutical targeting of AP endonuclease in multiple myeloma	TRP Basic
Thielemans	Kris	Vrije Universiteit Brussel	Immunotherapy targeting neo-epitopes in multiple myeloma	TRP Basic
Whetstone	Johnathan	Massachusetts General Hospital	Epigenetic Factors Impacting Leukemia Genome Stability and Drug Response	Scholar
Joshi	Neeraj	University of California, San Francisco	Identifying Ubiquitin ligase substrates important for progression of multiple myeloma	Fellow
Vakoc	Christopher	Cold Spring Harbor Laboratory	Targeting the chromatin reader protein TRIM33 as epigenetic therapy in B cell neoplasms	Scholar

LLS TAP Research Focus



Selective HDAC Inhibition: A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma (NCT01323751); Acetylon

Marrow Infiltrating Lymphocytes: Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma (NCT01858558); Johns Hopkins

BET Inhibition: Phase 1 Studies of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma (NCT01949883), AML/MDS and MM; Constellation

Disease Interception: A Prospective, Longitudinal, Observational Study in Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome; Dana Farber

LLS in the Cancer Innovation Ecosystem

